Developmental Funds

发展基金

• 批准号: 10413083
• 负责人: ROBERT S. MANNEL
• 金额: $ 26.55万
• 依托单位: UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-05-01 至 2023-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10413083
• 关键词: Address; Award; Biometry; Cancer Center; Cancer Center Support Grant; Clinical Cancer Center; Clinical Investigator; Clinical Sciences; Cytometry; Development; Direct Costs; Emerging Technologies; Ensure; Evaluation; Extramural Activities; Foundations; Funding; Funding Mechanisms; Goals; Grant; Growth; Health Technology; Investments; Leadership; Medical Research; Mission; Molecular Biology; Monitor; Oklahoma; Pathology; Peer Review; Pilot Projects; Play; Publications; Research; Research Design; Research Infrastructure; Research Personnel; Research Priority; Resource Allocation; Resource Sharing; Rest; Role; Science; Scientific Advances and Accomplishments; Secure; Services; Source; Strategic Planning; Structure; Therapeutic; Tissues; Underserved Population; anticancer research; base; cancer health disparity; cancer research center director; drug discovery; effectiveness evaluation; effectiveness outcome; innovation; interdisciplinary collaboration; mHealth; new technology; patient derived xenograft model; personalized cancer therapy; pre-clinical; programs; recruit; translational cancer research

DEVELOPMENTAL FUNDS – ABSTRACT Developmental funds from institutional, state and philanthropic sources have been critically important in the growth of the Stephenson Cancer Center (SCC) since its inception. Over the past five years, the SCC has utilized developmental funds to advance the following key research priorities defined in the SCC's 2012-2016 Strategic Plan: 1) stimulating transdisciplinary and collaborative science within the SCC's programs; 2) advancing scientific findings through the development pipeline into NCTN and other trials; 3) conducting research to address cancer health disparities among underserved populations in Oklahoma; 4) supporting early-stage clinical investigators who are actively involved in the SCC's clinical science effort; and 5) investing in new emerging technologies and technical services to support programmatically aligned cancer research at the SCC. All decisions concerning the allocation of developmental funds ultimately rest with the SCC Director, who meets with his senior leadership team biweekly to discuss new research opportunities and potential allocation of resources for intramural grants, recruitment, and investments in new technologies. Intramural pilot grants supported by developmental funds have played a major role in advancing the SCC's mission and goals, providing the means for the SCC to pursue new research opportunities and achieve broad strategic objectives as well as providing the means for program leaders to achieve targeted scientific objectives. The SCC has strategically utilized developmental funds through competitively awarded pilot project and directed-funding mechanisms, including a major team-based award mechanism to support multi-PI projects with high potential of leading to PPG submissions, to stimulate research and enhance transdisciplinary collaborations. Over the past five years (CY2012-2016), the SCC has awarded 59 pilot grants, with a total award amount of $3,910,492. To date, these grants have resulted in 106 peer-reviewed publications and $28,227,492 (total, direct cost) in extramural sponsored research funding (as of 4/15/17). Developmental funds have allowed the SCC to establish and enhance research infrastructure, including the Biostatistics and Research Design, Tissue Pathology, Molecular Biology and Cytometry Research, and Mobile Health Technology Shared Resources. For the upcoming five-year period, the SCC is requesting developmental funds to support the growth of a Patient-Derived Xenograft and Preclinical Therapeutics (PDX- PCT) Core housed at the Oklahoma Medical Research Foundation (OMRF), the SCC's proposed consortium partner. Established in 2015, this Core provides SCC investigators and other campus investigators with high- quality services for basic and translational cancer research, drug discovery and personalized cancer therapy. The goal is to develop the PDX-PCT Core into a formal shared resource within a five-year timeframe.

医疗基金-摘要 来自机构、国家和慈善机构的发展资金在2000年至关重要， 斯蒂芬森癌症中心（SCC）自成立以来的发展。在过去的五年里，SCC 利用发展基金推进SCC 2012-2016年确定的以下关键研究重点 战略计划：1）在SCC的计划中促进跨学科和合作科学; 2） 通过NCTN和其他试验的开发管道推进科学发现; 3）进行 研究解决俄克拉荷马州服务不足人群的癌症健康差异; 4）支持 积极参与SCC临床科学工作的早期临床研究者;以及5）投资 在新的新兴技术和技术服务，以支持规划一致的癌症研究， SCC。关于发展资金分配的所有决定最终由SCC主任作出， 他每两周与高级领导团队会面，讨论新的研究机会和潜力。 为校内赠款、招聘和新技术投资分配资源。 由发展基金支持的校内试点赠款在推进SCC方面发挥了重要作用 使命和目标，为SCC提供了追求新的研究机会和实现广泛的 战略目标，并为项目负责人提供实现有针对性的科学 目标. SCC通过竞争性授予的试点项目战略性地利用发展资金 和直接资助机制，包括一个主要的基于团队的奖励机制，以支持多个PI 具有很高潜力的项目，导致PPG提交，以刺激研究和加强跨学科 合作。在过去的五年里（CY 2012 -2016），SCC已经颁发了59个试点赠款， 金额为3910492元。到目前为止，这些赠款已导致106个同行评审的出版物， $28，227，492（总，直接成本）在校外赞助的研究资金（截至2017年4月15日）。 发展基金使SCC能够建立和加强研究基础设施，包括 生物统计学和研究设计，组织病理学，分子生物学和细胞计数研究，以及移动的 健康技术共享资源。在即将到来的五年期间，SCC要求 发展基金，以支持患者衍生的异种移植和临床前治疗（PDX- PCT）核心位于俄克拉荷马州医学研究基金会（OMRF），SCC提议的联盟 搭档成立于2015年，该核心提供SCC调查员和其他校园调查员高， 为基础和转化癌症研究、药物发现和个性化癌症治疗提供优质服务。 我们的目标是在五年时间内将PDX-PCT核心开发成正式的共享资源。